FEMSelect Overview
FEMSelect is the developer of EnPlace, a minimally invasive and mesh-free system for pelvic floor ligament fixation. The EnPlace procedure takes approximately 30 minutes. Its patented delivery system enables precise guidance, insertion, and deployment of the anchor unit, which is designed to be introduced through the vaginal wall and secured to the pelvic floor ligament to provide stabilization. EnPlace is FDA cleared and CE marked. The device is a combination of a Nitinol-based anchor, surgical sutures, and an innovative attachment method, and the surgery is conducted with no deep dissection or mesh. EnPlace has been tested in a human trial in Israel and is protected by global and U.S. patents.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
FEMSelect transforms women's quality of life with innovative pelvic floor solutions | CTech
FEMSelect, an Israel-based company, aims to enhance womens quality of life through their solution for pelvic organ prolapse. They offer a minimally invasive approach called EnPlace, which is the only solution of its kind on the market. Other existing solutions are highly invasive and involve long recovery periods. FEMSelect recently raised $9 million in their Series B funding round led by TriVentures and co-led by New Age Ventures. The global market for medical devices addressing pelvic organ prolapse is estimated to be worth $10 billion. FEMSelects mission aligns with the growing demand for womens health solutions, particularly for those affected by childbirth, menopause, and aging.
CustomersInvestment
growth-positive
FEMSelect Raises US$9M in Series B Financing
FEMSelect, a Tel Aviv-based developer of an innovative approach to pelvic floor ligament fixation, has raised US$9M in Series B funding. The investment will support the growth and market penetration of their product, EnPlace®, primarily in the US. EnPlace® is a minimally invasive, meshless approach to pelvic floor ligament fixation that is cleared by the FDA. FEMSelect has partnered with womens healthcare company LiNA Medical USA and has obtained a procedure code from CMS, enabling healthcare facilities to receive reimbursement for the procedure. The technology is currently available in more than 25 states across the US.
InvestmentPartners
growth-positive
FEMSelect, Ltd. Announces CMS Reimbursement for Innovative Minimally Invasive Approach to Pelvic Organ Prolapse Repair Procedure
FEMSelect, a medical device company, has announced that the Centers for Medicare and Medicaid Services (CMS) has created a new HCPCS code to describe the procedure associated with its EnPlace system. The EnPlace procedure is positioned for appropriate payment as a Level 5 GYN procedure and designated as device-intensive, enabling broader access to EnPlace for women in ambulatory surgery centers. This is a major milestone for FEMSelect and the clinical community, as it provides reimbursement for a procedure that addresses pelvic organ prolapse, a condition that affects millions of women in the U.S. The EnPlace technology is available nationwide through FEMSelects exclusive partner in the U.S., LiNA Medical USA.
Customers
growth-positive
FemSelect closes enrollment for mesh-free pelvic floor device study
FemSelect has closed enrollment for the EnPlace post-market study of its mesh-free pelvic floor repair device. The study aims to assess the long-term safety, durability, clinical effectiveness, and cost-effectiveness of the EnPlace system for vaginal colpopexy in uterine prolapse treatment. The company plans to do a limited launch in the U.S. in Q4 2019 following a Round B fundraising. The study is estimated to be completed by August 31, 2024.
CustomersInvestment
growth-positive
Mid Atlantic Bio Angels Initiates Second Investment Pool and Makes Inaugural Investment in POP Medical Solutions, Ltd.
Mid Atlantic Bio Angels (MABA) has announced the initiation of a second closed-end investment pool funded by current members. The inaugural investment from this pool has been made into Israel-based POP Medical Solutions, which focuses on the treatment of pelvic organ prolapse (POP). MABAs first investment pool was fully invested within 18 months and invested in several companies. The second pool is twice as large as the first. POP Medical has developed a minimally-invasive surgical system called NeuGuide for the treatment of POP. The company has received FDA clearance for the product and plans to complete a post-marketing study, gain European CE Mark Certification, transfer the product to mass production, and build a commercial organization in the US.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $16.89M |
| Last funding | $540K |
| Stage | B |
| Rounds | 7 |
| Investors | 14 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | www.femselect.com |
Locations
HaMa'ayan Street 2, Modi'in-Maccabim-Re'ut, Israel
7 Creek Bend Court, Newark, DE, USA
Photos & Videos
2 item(s)
